In vitro-metabolism of 3H-progesterone in human testicular tissue: IV Before and after long-term gonadotrophin treatment; including one 47, XYY-male.
Certain defects in the intratesticular androgen biogenetic system may lead to a significant impairment of gonadal function in total in the human male. In the present investigation, four males with impaired reproductive performance were analysed before and after long term treatment with gonadotrophic hormones with regard to their in vitro metabolism of 3H-progesterone in testicular incubates; one of whom representing the first instance of an XYY-male studied in some detail with regard to intratesticular steroidogenesis. A steroid metabolisc pattern of an "immature" type, i.e., possibly indicating a relative understimulation of the gonads by gonadotrophic hormones, in vivo, was found in one of the four patients, i.e., the XYY-male, inspite of normal levels of gonadotrophic hormones in the peripheral circulation. Gametic output was found to increase significantly during the course of gonadotrophin substitution therapy, and the individual steroid metabolic pattern also changed drastically towards a more mature type subsequent to therapy. In a second patients, who originally presented with completely immotile sperm, a certain shift in the steroid metabolic pattern was observed after the gonadotrophin therapy in favour of increasing relative amounts of 17a-hydroxyprogesterone, concurrent with a decreasing proportion of dead sperm, and a certain, though minimal, improvement in sperm kinetics. The last two patients, with originally mature types of in vitro steroid metabolism in testicular incubates, displayed no changes in steroid metabolic patterns or spermiogram qualities subsequent to the gonadotrophin therapy. However, one of them might have been azoospermic because of anatomical reasons. The present demonstration that an individual steroid metabolic pattern in testicular incubates under certain conditions may be deliberately modified as expected, by long term gonadotrophin therapy, further supports our previous suggestion that the relative proportions of newly synthesized and recovered deltal4-3-oxo-C21-steroids in testicular incubates, especially 20a-dihydroprogesterone and 17a-hydroxyprogesterone, may well reflect the actual gonadotrophic stimulation in a particular individual at the time of testicular biopsy. Investigations of individual steroid metabolic patterns in testicular incubates may therefore contribute useful information for the adequate selection of patients with disturbed gonadal function, who may benefit from gonadotrophin substitution therapy.
D004092:20-alpha-Dihydroprogesterone / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000523:Algestone / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000627:therapeutic use; D006062:Gonadotropins / Q000627:therapeutic use*; D006801:Humans; D006908:Hydroxyprogesterones / Q000378:metabolism; D007248:Infertility, Male / Q000188:drug therapy / Q000378:metabolism; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008596:Menotropins / Q000627:therapeutic use; D011374:Progesterone / Q000378:metabolism*; D012729:Sex Chromosome Aberrations / Q000188:drug therapy / Q000378:metabolism; D013081:Sperm Motility; D013737:Testis / Q000378:metabolism* / Q000473:pathology; D013739:Testosterone / Q000097:blood
D006063:Chorionic Gonadotropin; D006062:Gonadotropins; D006908:Hydroxyprogesterones; D004092:20-alpha-Dihydroprogesterone; D000523:Algestone; D013739:Testosterone; D011374:Progesterone; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone